BridgeBio Pharma Inc
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
BBIO$77.93+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | 143 |
| Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023 | 145 |
| Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022 | 146 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022 | 147 |
| Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit for the years ended December 31, 2024, 2023 and 2022 | 148 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022 | 149 |
| Notes to Consolidated Financial Statements | 151 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.